Literature DB >> 12531815

Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma.

Niklas Zojer1, Heinz Ludwig, Michael Fiegl, Freda K Stevenson, Surinder S Sahota.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) can transform to multiple myeloma (MM). In myeloma, mutated V(H) genes with sequence homogeneity reveal a postfollicular origin. Previously, some MGUS cases showed mutated V(H) genes with intraclonal variation, indicating an earlier stage of arrest. We investigated progression from 2 of 2 MGUS to MM, in which V(H) genes confirmed clonal evolution. In one MGUS case, intraclonal heterogeneity was evident, and transformation to myeloma occurred rapidly with apparent homogeneity in the emergent clone. However, residual MGUS-derived sequences were detectable at this time. Heterogeneity in MGUS does not associate with benign disease, but it indicates an origin from a tumorigenic cell, most likely surface immunoglobulin(+), undergoing somatic mutation. The remaining case displayed intraclonal homogeneity at the MGUS stage, conceivably resulting from a self-cloning outgrowth from MGUS with heterogeneity. Transformation can occur at either MGUS stage, but it involves a single cell in which somatic mutation is then silent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531815     DOI: 10.1182/blood-2002-09-2825

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

2.  The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

Authors:  N Puig; I Conde; C Jiménez; M E Sarasquete; A Balanzategui; M Alcoceba; J Quintero; M C Chillón; E Sebastián; R Corral; L Marín; N C Gutiérrez; M-V Mateos; M González-Díaz; J F San-Miguel; R García-Sanz
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 3.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

4.  Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.

Authors:  Shiny Nair; Andrew R Branagan; Jun Liu; Chandra Sekhar Boddupalli; Pramod K Mistry; Madhav V Dhodapkar
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

5.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

6.  Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing.

Authors:  Renee C Tschumper; Yan W Asmann; Asif Hossain; Paul M Huddleston; Xiaosheng Wu; Angela Dispenzieri; Bruce W Eckloff; Diane F Jelinek
Journal:  Oncotarget       Date:  2012-04

7.  Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma.

Authors:  Graeme Cowan; Nicola J Weston-Bell; Dean Bryant; Anja Seckinger; Dirk Hose; Niklas Zojer; Surinder S Sahota
Journal:  Oncotarget       Date:  2015-05-30

8.  Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.

Authors:  Giada Bianchi; Irene M Ghobrial
Journal:  Curr Cancer Ther Rev       Date:  2014

Review 9.  Game of Bones: How Myeloma Manipulates Its Microenvironment.

Authors:  Tyler Moser-Katz; Nisha S Joseph; Madhav V Dhodapkar; Kelvin P Lee; Lawrence H Boise
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.